Cover Image
市場調查報告書

全球液態切片市場

LIQUID BIOPSY MARKETS by Cancer Type by Diagnosis, Monitoring & Recurrence Testing. 2019-2023 w. Historical Data Including Screening Market Potential Size with Executive and Consultant Guides

出版商 Howe Sound Research 商品編碼 461040
出版日期 內容資訊 英文 285 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球液態切片市場 LIQUID BIOPSY MARKETS by Cancer Type by Diagnosis, Monitoring & Recurrence Testing. 2019-2023 w. Historical Data Including Screening Market Potential Size with Executive and Consultant Guides
出版日期: 2018年07月12日 內容資訊: 英文 285 Pages
簡介

本報告提供全球液態切片市場相關調查分析,15個國家、4個地區為對象,市場概要,市場趨勢,市場預測等系統性資訊。

第1章 簡介與市場定義

  • 所謂液態切片
  • 定序革命
  • 市場定義
  • 調查手法
  • 液態切片的支出預測

第2章 市場概要

  • 動態市場上企業
  • 活體組織切片的使用
  • 活體組織切片網站
  • 目前情形:活體組織切片分析
  • 癌症的證據:液態切片技術
  • 癌症治療協議具批判性
  • 產業結構
  • 主要企業的簡介
    • Qiagen
    • Agena Bioscience
    • Angle plc
    • ApoCell
    • Biocept
    • BioFluidica
    • Bio-Rad Laboratories
    • Boreal Genomics
    • Chronix Biomedical
    • Clearbridge BioMedics
    • Cynvenio
    • Cytolumina Technologies Corp
    • CytoTrack
    • Diagnologix LLC
    • Epic Sciences
    • Exosome Diagnostics
    • Exosome Sciences
    • Fluidigm Corp
    • Fluxion Biosciences
    • Genomic Health
    • GRAIL
    • Guardant Health
    • HansaBiomed
    • Horizon Discovery
    • iCellate
    • Illumina
    • Inivata
    • Janssen Diagnostics
    • Molecular MD
    • Myriad Genetics
    • Natera
    • New Oncology
    • Roche Diagnostics
    • RainDance Technologies
    • Rarecells SAS
    • Silicon Biosystems
    • Sysmex Inostics
    • SRI International
    • Thermo Fisher
    • Trovagene
    • Freenome
    • Personal Genome Diagnostics
    • MDx Health
    • Bioarray Genetics
    • Oncocyte
    • Circulogene
    • Integrated Diagnostics
    • Bio Cartis
    • Clinical Genomics
    • OncoDNA

第3章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 檢查裝置與自動化
  • 診斷技術的發展

第4章 液態切片的最近的發展

第5章 各國市場規模:北美

  • 美國
  • 加拿大

第6章 各國市場:歐洲

  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 其他,舊蘇聯

第7章 各國市場:亞太地區

  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 其他

第8章 各國市場:南美,非洲、中東

  • 巴西
  • 墨西哥
  • 其他南美
  • 非洲、中東

第9章 全球市場摘要

  • 全球市場

第10章 潛在的市場機會規模

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

OVERVIEW:

The Diagnostic, Therapy Monitoring, Recurrence Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2023. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers as well as breakouts by Diagnostic, Therapy Monitoring and Recurrence Monitoring.

What is the size of the huge screening opportunity? They are all listed in Chapter 10.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Liquid Biopsy Market - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. What is Liquid Biopsy?
  • 1.2. The Sequencing Revolution
  • 1.3. Market Definition
    • 1.3.1. Volumes
    • 1.3.2. Prices
    • 1.3.3. Revenue Market Size
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. A Spending Perspective on Liquid Biopsy
    • 1.5.1. An Historical Look at Clinical Testing

2. Market Overview

  • 2.1. Players in a Dynamic Market
    • 2.1.1. Academic Research Lab
    • 2.1.2. Diagnostic Test Developer
    • 2.1.3. Genomic Instrumentation Supplier
      • 2.1.3.1. Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4. Pharmaceutical/Reagent Supplier
    • 2.1.5. Independent Testing Lab
    • 2.1.6. Public National/regional lab
    • 2.1.7. Hospital lab
    • 2.1.8. Physician Lab
    • 2.1.9. Audit Body
    • 2.1.10. Certification Body
  • 2.2. Using Biopsies
    • 2.2.1. Cancer
    • 2.2.2. Precancerous conditions
    • 2.2.3. Inflammatory conditions
  • 2.3. Biopsy Sites
  • 2.4. The Situation Today - Biopsy Analysis
  • 2.5. Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1. The Big Picture on Liquid Biopsy Technology
    • 2.5.2. The Role of CTCs
      • 2.5.2.1. Types of CTCs
      • 2.5.2.2. CellSearch Detection- Ultimate Sensitivity
      • 2.5.2.3. Epic Sciences Detection- Imaging Takes the Lead
      • 2.5.2.4. Maintrac Detection - The Microscope
      • 2.5.2.5. Other Methods
    • 2.5.3. ctDNA - Going Mainstream?
    • 2.5.4. Exosomes and Micro Vesicles - New Kid on Block
    • 2.5.5. The Multiple Play
  • 2.6. Cancer Treatment Protocol Under Siege
    • 2.6.1. Issues and Limitations to Liquid Biopsy Adoption - Double Diagnostics
    • 2.6.2. The Cancer Screening Market Opportunity
      • 2.6.2.1. GRAIL - What Is It?
    • 2.6.3. Cancer Management vs. Diagnosis
      • 2.6.3.1. The Role of Risk Assessment
      • 2.6.3.2. Managing Therapy
      • 2.6.3.3. Monitoring Disease - What Is It?
    • 2.6.4. Phases of Adoption - Looking Into The Future
    • 2.6.5. The Promise of Liquid Biopsy
  • 2.7. Structure of Industry Plays a Part
    • 2.7.1. Hospital Testing Share
    • 2.7.2. Economies of Scale
      • 2.7.2.1. Hospital vs. Central Lab
    • 2.7.3. Physician Office Lab's
    • 2.7.4. Physician's and POCT
  • 2.8. Profiles of Key Players
    • 2.8.1. Qiagen
    • 2.8.2. Agena Bioscience
    • 2.8.3. Angle plc
    • 2.8.4. ApoCell
    • 2.8.5. Biocept
    • 2.8.6. BioFluidica
    • 2.8.7. Bio-Rad Laboratories
    • 2.8.8. Boreal Genomics
    • 2.8.10. Chronix Biomedical
    • 2.8.11. Clearbridge BioMedics
    • 2.8.12. Cynvenio
    • 2.8.13. Cytolumina Technologies Corp
    • 2.8.14. CytoTrack
    • 2.8.15. Diagnologix LLC
    • 2.8.16. Epic Sciences
    • 2.8.17. Exosome Diagnostics
    • 2.8.18. Exosome Sciences
    • 2.8.19. Fluidigm Corp
    • 2.8.20. Fluxion Biosciences
    • 2.8.21. Genomic Health
    • 2.8.39. GRAIL
    • 2.8.22. Guardant Health
    • 2.8.23. HansaBiomed
    • 2.8.23. Horizon Discovery
    • 2.8.24. iCellate
    • 2.8.25. Illumina
    • 2.8.26. Inivata
    • 2.8.27. Janssen Diagnostics
    • 2.8.28. Molecular MD
    • 2.8.29. Myriad Genetics
    • 2.8.30. Natera
    • 2.8.31. New Oncology
    • 2.8.32. Roche Diagnostics
    • 2.8.33. RainDance Technologies
    • 2.8.34. Rarecells SAS
    • 2.8.35. Silicon Biosystems
    • 2.8.36. Sysmex Inostics
    • 2.8.37. SRI International
    • 2.8.38. Thermo Fisher
    • 2.8.39. Trovagene
    • 2.8.40. Freenome
    • 2.8.41. Personal Genome Diagnostics
    • 2.8.42. MDx Health
    • 2.8.43. Bioarray Genetics
    • 2.8.44. Bio-Techne
    • 2.8.45. Oncocyte
    • 2.8.46. Circulogene
    • 2.8.47. Incell Dx
    • 2.8.48. Integrated Diagnostics
    • 2.8.49. Bio Cartis
    • 2.8.50. Clinical Genomics
    • 2.8.51. OncoDNA
    • 2.8.52. Biodesix Inc.
    • 2.8.53. CellMax Life

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Non Invasive Game Changer
    • 3.1.2. Lower Cost
    • 3.1.3. Greater Accuracy.
    • 3.1.4. Wide Range of Potential Uses
    • 3.1.5. Aging Population
  • 3.2. Factors Limiting Growth
    • 3.2.1. Lower prices
    • 3.2.2. Lack of Standards.
    • 3.2.3. Protocol Resistance.
    • 3.2.4. Initial Adoption Has No Cost Savings
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution
    • 3.4.2. Impact of NGS on pricing
    • 3.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4. CGES Testing, A Brave New World
    • 3.4.5. Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1. Recent Developments - Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
  • 4.2. Biodesix Acquires Integrated Diagnostics
  • 4.3. Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
  • 4.4. Bio-Techne to Acquire Exosome Dx for Up to $575M
  • 4.5. GRAIL Announces Data on Detection of Early-Stage Lung Cancers
  • 4.6. CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests
  • 4.7. Personal Genome Diagnostics Nets $75M in Series B Financing
  • 4.8. Circulogene Licenses Liquid Biopsy Tech to Turkish Lab
  • 4.9. Genomic Health, Cleveland Diagnostics Ink Deal to Commercialize Prostate Cancer Tests
  • 4.10. Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests
  • 4.11. OncoCyte Q3 Net Loss Swells, Lung Cancer Dx Launch Delayed
  • 4.12. Natera, Aarhus University Collaborate on Liquid Biopsy Study for Colorectal Cancer
  • 4.13. MDxHealth Nine-Month Revenues Up 38 Percent
  • 4.14. Clinical Genomics, MSKCC to Study Rectal Cancer Liquid Biopsy Monitoring
  • 4.15. Collaboration in Japan Using Exosomes for Better Cancer Diagnoses, Treatment
  • 4.16. Cancer MDx Firm Bioarray Genetics Raises $4M
  • 4.17. Biocept Inks US Marketing Deal for Target Selector Liquid Biopsy Tech
  • 4.18. Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test
  • 4.19. Angle to Buy Axela, Plans to Raise £12.2M in Share Placement
  • 4.20. Mutation Count in ctDNA Predicts Patient Response to Immunotherapy
  • 4.21. Qiagen, Angle to Comarket Liquid Biopsy Technologies
  • 4.22. Cancer MDx Firm Bioarray Genetics Raises $4M
  • 4.23. Genentech Adapts Microfluidics Sequencing Method for Liquid Biopsy Applications
  • 4.24. OncoDNA Gains UK Reimbursement for OncoStrat&Go
  • 4.25. Sequencing of Circulating Tumor DNA Detects Early Cancers
  • 4.26. RareCyte announces $30M round
  • 4.27. Liquid Biopsies May Never Replace Tissue Biopsies
  • 4.28. Karius reels in $50M to ramp up infectious disease liquid biopsy
  • 4.29. Liquid Biopsy Passes Test for Nasopharyngeal Cancer
  • 4.30. Exosome Diagnostics Launches the MedOncAlyzer™ Pan-Cancer Panel
  • 4.31. Lonza Acquires HansaBioMed, Invests in Exosomics
  • 4.32. Controversial Test Highlights Precision Medicine Marketing, Regulatory Issues
  • 4.33. Trovagene Announces Agreement with Global Biopharmaceutical Company
  • 4.34. Liquid Biopsy Firms Move Toward Multianalyte Detection
  • 4.35. In a first, China approves Amoy's lung cancer liquid biopsy
  • 4.36. Liquid Biopsy Shows Promise for Colon Cancer
  • 4.37. Bio-Rad Continues to Advance Digital PCR Tech, Liquid Biopsy Tests Into Commercial Clinical Market
  • 4.38. Liquid Biopsy Combo Improved Sensitivity for EGFR Mutations in NSCLC
  • 4.39. Startups race to develop cancer screens from DNA
  • 4.40. Bristol-Myers, NEA drive cancer test player to $75M round
  • 4.41. Dutch Researchers Develop ThromboSeq Test to Detect Lung Cancer
  • 4.42. Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics
  • 4.43. OncoDNA Inks Russian Distribution Deal With Genext
  • 4.44. Biocept Prices $15M Public Offering
  • 4.45. UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
  • 4.46. Exact Sciences Shares Drop on Threat From Liquid Biopsy

5. Country Market Sizes - North America

  • 5.1. United States of America
    • 5.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 5.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 5.2. Canada
    • 5.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 5.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1. France
    • 6.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.2. Germany
    • 6.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.3. United Kingdom
    • 6.3.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.3.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.3.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.3.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.3.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.3.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.4. Spain
    • 6.4.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.4.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.4.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.4.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.4.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.4.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.5. Italy
    • 6.5.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.5.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.5.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.5.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.5.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.5.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.6. Russia
    • 6.6.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.6.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.6.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.6.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.6.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.6.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.7. Remainder of Europe and Former Soviet Union
    • 6.7.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.7.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.7.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.7.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.7.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.7.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1. China
    • 7.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.2. Japan
    • 7.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.3. South Korea
    • 7.3.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.3.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.3.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.3.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.3.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.3.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.4. India
    • 7.4.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.4.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.4.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.4.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.4.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.4.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.5. Australia
    • 7.5.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.5.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.5.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.5.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.5.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.5.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.6. Rest of Asia Pacific
    • 7.6.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.6.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.6.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.6.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.6.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.6.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1. Brazil
    • 8.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.2. Mexico
    • 8.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.3. Rest of Latin America
    • 8.3.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.3.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.3.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.3.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.3.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.3.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.4. Africa and The Middle East
    • 8.4.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.4.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.4.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.4.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.4.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.4.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1. Global
    • 9.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 9.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 9.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 9.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 9.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 9.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

10. Potential Market Opportunity Sizes

  • 10.1. Cancer Screening by Country: Lung, Breast & Colorectal
  • 10.2. Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 10.3. Potential Market Size - Cancer Diagnosis
  • 10.4. Potential Market Size - Cancer Management

Appendices

I. United States Medicare System: January 2018 Clinical Laboratory Fees Schedule - National Limit and Midpoint

II. FDA Approved Human Genetic Tests

III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1: Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2: Market Players by Type
  • Table 3: Biopsy Sites
  • Table 4: Advantages of Liquid Biopsy in Screening Market
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 10: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 11: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 12: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 13: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 14: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 15: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 16: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 17: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 18: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 19: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 20: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 21: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 22: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 23: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 24: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 25: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 26: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 27: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 28: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 29: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 30: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 31: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 32: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 33: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 34: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 35: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 36: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 37: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 38: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 39: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 40: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 41: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 42: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 43: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 44: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 45: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 46: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 47: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 48: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 49: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 50: All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 51: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 52: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 53: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 54: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 55: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 56: All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 57: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 58: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 59: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 60: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 61: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 62: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 63: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 64: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 65: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 66: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 67: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 68: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 69: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 70: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 71: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 72: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 73: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 74: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 75: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 76: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 77: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 78: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 79: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 80: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 81: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 82: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 83: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 84: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 85: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 86: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 87: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 88: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 89: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 90: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 91: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 92: All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 93: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 94: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 95: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 96: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 97: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 98: All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 99: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 100: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 101: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 102: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 103: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 104: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 105: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 106: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 107: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 108: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 109: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 110: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 111: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 112: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 113: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 114: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 115: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 116: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 117: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 118: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 119: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 120: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 121: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 122: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 123: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 124: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 125: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 126: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 127: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 128: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 129: Potential Screening Market: Lung, Breast & Colorectal
  • Table 130: Potential Screening Market: Prostate, Other & All
  • Table 131: Potential Cancer Diagnosis Market Size
  • Table 132: Potential Cancer Management Market Size
  • Table 133: 2018 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2: Comparison of Liquid Biopsy Classes
  • Figure 3: Characteristics of Different Vesicle Types
  • Figure 4: Percentage of World Population Over 65
Back to Top